Overview

Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of perifosine in treating patients who have refractory solid tumors or hematologic cancer.
Phase:
Phase 1
Details
Lead Sponsor:
National Cancer Institute (NCI)